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South Carolina influenza surveillance consists of voluntary and mandatory 
components.  State-mandated influenza-related reportable conditions are:  
♦ positive influenza cultures 
♦ positive rapid antigen tests 
♦ influenza A, novel or avian  
♦ influenza-related deaths 
♦ influenza hospitalizations (NEW) 
The voluntary influenza monitoring networks are:  
♦ Viral Isolate Network 
♦ Influenza-like Illness Network (ILINet) 
Virologic Surveillance. Positive viral cultures are reportable within 7 days. In addition, a network of sentinel physicians 
submit a sampling of isolates for testing at the DHEC Bureau of Labs (BOL).  Since October 4, 2008, BOL has reported 
1106 positive influenza specimens. Another 513 positive specimens have been reported by other labs. 
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Vaccination is the best way to prevent influenza and its 
complications. Approximately 83% of the United States 
population is specifically recommended for annual 
vaccination against seasonal influenza; however, <40% 
received the 2008-09 influenza vaccine (Centers for 
Disease Control and Prevention (CDC), 2009c).  
Recommendations. This season, full protection from 
influenza will require both novel influenza A (H1N1) and 
seasonal influenza vaccines. Fortunately, seasonal 
influenza vaccines are available early this year and CDC 
recommends that vaccination begin as soon as possible. 
Since there is no clinically important waning immunity 
related to early season vaccination (Skronski, et al, 2008), 
patients vaccinated early will still have good protection 
later in the influenza season.  
CDC has published new recommendations for seasonal 
influenza vaccination (CDC, 2009c). This guidance 
includes a new emphasis for seasonal influenza 
vaccination for all children ages 6 months to 18 years; 
previously the pediatric focus was on children 6 months 
to 4 years of age. 
CDC has also issued recommendations for the novel 
influenza A (H1N1) vaccine (CDC, 2009d). This vaccine 
represents a strain change to the seasonal influenza 
vaccine and it has been found to be safe. Thus, although 
this vaccine is new, it is not experimental. The FDA 
approved it September 15, 2009. It does not contain an 
adjuvant (CDC, 2009a) and it is being made using the 
(Continued on page 2) 
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same processes and facilities that are used to make 
seasonal influenza vaccines (CDC, 2009b; FDA, 2009).  
Safety Profile & Monitoring. Over the years, hundreds 
of millions of Americans have received seasonal influenza 
vaccines. The most common side effects are mild, such as 
soreness, redness, or swelling at the injection site. It is 
expected that the novel influenza A (H1N1) vaccine will 
continue to have a safety profile similar to seasonal 
influenza vaccine (CDC, 2009a). Providers are reminded 
to report any clinically significant adverse event that 
occurs after the administration of any vaccine licensed in 
the United States, including the new novel influenza A 
(H1N1) vaccine, to the federal Vaccine Adverse Event 
Reporting System (VAERS: http://www.vaers.hhs.gov). Of 
particular interest are cases of Guillain-Barré Syndrome 
(GBS) occurring after novel influenza A (H1N1) vaccine. 
However, there is no reason to suspect this will occur in 
association with the vaccine. The novel influenza A 
(H1N1) virus is genetically different from the 1976 “Swine 
Flu” virus (CDC, 2009b) whose vaccine was associated 
with cases of GBS (approximately 1 additional case per 
100,000 people who received the vaccine) (CDC, 2009a). 
CDC has implemented enhanced safety monitoring for the 
novel influenza A (H1N1) vaccine and DHEC will work 
with CDC to ensure serious adverse events related to the 
vaccine are reported and investigated. 
Immunization Campaigns. This year’s influenza 
vaccination season presents one of the biggest challenges 
faced by public health in recent memory. The demand for 
both vaccines is expected to exceed what public health 
could deliver on its own. As a result, DHEC has partnered 
with other providers to assure that all South Carolinians 
have the opportunity to be vaccinated. DHEC invited 
healthcare providers in various types of practice settings 
(including medical offices, hospitals, pharmacies, schools, 
and universities) to volunteer to provide the novel 
influenza A (H1N1) vaccine through a health alert 
network (HAN) notice this summer. The response was 
encouraging, with over 1,700 providers pre-registering to 
provide this vaccine. Pre-registration is temporarily closed 
while DHEC undergoes the final registration of these 
providers. The first group of final registrants will include 
providers most able to reach the target populations (Box). 
The novel influenza A (H1N1) vaccine is expected by mid-
October and will be available at DHEC clinics, schools and 
with providers who complete the final registration 
process. Because initial doses will be limited, the vaccine 
will be given to target populations first. As supplies 
increase, vaccination will be available to everyone.  
For more information, visit http://www.cdc.gov/h1n1flu/
vaccination/. To identify vaccine clinics near you (or to list 
your vaccine clinic) visit http://
www2.thecarolinascenter.org/FCF/fluclinicfinder.aspx. 
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BOX. Initial target groups for novel influenza A (H1N1) vaccination programs and a subset of these target 
groups to receive vaccine if initial vaccine availability is not sufficient to meet demand* 
Initial target groups 
ACIP recommends that programs and providers provide vaccine to all persons in the following five initial target groups 
as soon as vaccine is available (order of target groups does not indicate priority): 
♦ pregnant women, 
♦ persons who live with or provide care for infants aged <6 months (e.g., parents, siblings, and daycare 
providers), 
♦ health-care and emergency medical services personnel †,  
♦ children and young adults aged 6 months–24 years, and 
♦ persons aged 25–64 years who have medical conditions that put them at higher risk for influenza-related 
complications.§ 
Subset of initial target groups 
ACIP recommends that all persons in the following subset of the five initial target groups receive priority for 
vaccination if vaccine availability is not sufficient to meet demand (order of target groups does not indicate priority): 
♦ pregnant women, 
♦ persons who live with or provide care for infants aged <6 months (e.g., parents, siblings, and daycare 
providers), 
♦ health-care and emergency medical services personnel who have direct contact with patients or infectious 
material, 
♦ children aged 6 months–4 years, and 
♦ children and adolescents aged 5–18 years who have medical conditions that put them at higher risk for 
influenza-related complications.§ 
Footnotes 
* Priority should be given to persons in the subset of the five target groups only if initial vaccine availability is not sufficient to meet 
demand for all persons in the five target groups. As vaccine availability increases, vaccination programs should be expanded to 
include all members of the initial target groups. Vaccination of other adult populations is recommended as vaccine availability 
increases. 
† Health-care personnel (HCP) include all paid and unpaid persons working in health-care settings who have the potential for 
exposure to patients with influenza, infectious materials, including body substances, contaminated medical supplies and 
equipment, or contaminated environmental surfaces. HCP might include (but are not limited to) physicians, nurses, nursing 
assistants, therapists, technicians, emergency medical service personnel, dental personnel, pharmacists, laboratory personnel, 
autopsy personnel, students and trainees, contractual staff not employed by the health-care facility, and persons (e.g., clerical, 
dietary, housekeeping, maintenance, and volunteers) not directly involved in patient care but potentially exposed to infectious 
agents that can be transmitted to and from HCP. The recommendations in this report apply to HCP in acute-care hospitals, nursing 
homes, skilled nursing facilities, physicians’ offices, urgent care centers, and outpatient clinics, and to persons who provide home 
health care and emergency medical services. Emergency medical services personnel might include persons in an occupation (e.g., 
emergency medical technicians and fire fighters) who provide emergency medical care as part of their normal job duties. 
§ Medical conditions that confer a higher risk for influenza-related complications include chronic pulmonary (including asthma), 
cardiovascular (except hypertension), renal, hepatic, cognitive, neurologic/neuromuscular, hematologic, or metabolic disorders 
(including diabetes mellitus) and immunosuppression (including immuno-suppression caused by medications or by human 
immunodeficiency virus). 
Source: MMWR 2009 RR-10, p. 6 (http://www.cdc.gov/mmwr/PDF/rr/rr5810.pdf)  
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Epidemiology.  Brucellosis is a nationally notifiable 
disease that is found rarely in humans in the United 
States.  In 2007, the Centers for Disease Control and 
Prevention (CDC) reported that Brucellosis was detected 
at a rate of less than 0.5 cases per 100,000 people in the 
US (CDC, 2007).  During that year, one confirmed case in 
SC was reported to SC DHEC, which corresponds to .02 
Brucellosis cases per 100,000 population.  (SC DHEC, 
2009)  Human Brucellosis occurs more commonly in 
developing nations, where high quality animal husbandry 
and hygiene are not practiced. 
Four species of Brucella organisms cause most cases of 
human disease.  Brucella melitensis, which is transmitted 
by infected goats and sheep, is the most frequently 
isolated species of Brucella in the US.  Brucella abortus 
(from cattle), suis (from swine), and canis (from dogs) 
are the other species that cause significant numbers of 
cases of human Brucellosis (CDC, 2007).  
Clinical and Laboratory Findings in Brucellosis.  
Brucellosis is characterized by fever, chills, lethargy, night 
sweats, myalgia, arthralgia, depression, and weight loss.  
Clinical onset may be acute, insidious, or recurring.  
Clinical course is variable, and the symptoms may persist 
for days to months, with occasional untreated cases 
lasting more than a year.  Chronic sequellae are common.  
Osteoarticular complications represent the most common 
chronic manifestations found, occurring in 20-60% of 
cases.  Orchitis, epididymitis, and endocarditis comprise 
the other frequent chronic sequellae of this disease.   
Often, symptoms of Brucellosis will relapse, even after a 
patient has undergone recommended therapy, proving 
the basis for the disease’s common name, “Undulant 
Fever”.  The incubation period for this disease is quite 
variable, but most often ranges from 5 to 60 days 
(Heymann, 2008).  Cases of Brucellosis are laboratory 
confirmed by either: isolation, a four-fold or greater 
increase in agglutination titers between acute and 
convalescent samples, or immunofluorescense.  
Transmission and Risks.  Brucella spp organisms are 
found in the placenta, blood, milk, urine, and other 
tissues of infected animals.  Transmission to humans 
occurs through three routes: inhalation, ingestion, 
and contamination of wounds with infectious 
materials.  Ingestion of unpasteurized dairy products is 
a major source of human Brucellosis.   
Certain occupations also have high risk of exposure to 
Brucella spp due to their frequent contact with animals; 
these include abattoir workers, veterinarians, and 
farmers.  Individuals in these occupations should take 
care to wear proper protective clothing, wash away any 
animal tissues and body fluids in contact, and dispose of 
animal tissues/fluids appropriately, to decrease their risk 
of exposure to Brucella organisms.   
Laboratorians are also at greater risk of exposure to 
Brucella spp, due to their work with isolates in clinical 
specimens.  In fact, Brucellosis is one of the most 
common laboratory-acquired bacterial infections.  
Laboratorians should handle all isolates of Brucella spp in 
Biosafety Level 3 (BSL 3) facilities, according to CDC 
guidelines.  All manipulations of Brucella spp organisms 
should be performed by laboratorians under Class II or 
higher biological safety cabinets, utilizing appropriate 
protective procedures.  Whenever Brucella spp are 
suspected by clinicians, laboratory specimens and 
requests should be appropriately labeled, in order to try 
to prevent accidental exposure of laboratorians, who 
might manipulate these specimens without the benefit of 
BSL3 precautions (CDC, 2006).   
Hunters of feral swine are also at increased risk of 
exposure to Brucella suis.  Serologic studies have shown 
Brucella suis to be endemic in feral swine in South 
Carolina.  (5) Hunters may potentially be exposed to 
Brucella suis organisms during the dressing of killed feral 
hogs.  Additionally, workers in deer processing plants, 
that also process feral swine, have an increased risk of 
exposure to Brucella suis organisms.  South Carolina 
currently has six combination deer and feral swine 
processing plants.  This spring, SC DHEC received report 
of a confirmed Brucellosis case in an individual, who 
contracted the disease through the processing of feral 
hogs at such a facility.  Processors of feral swine should 
take precautions to wear protective clothing, gloves, and 
masks during this activity to avoid infection with Brucella 
suis (CDC, 2009a). 
Resources for More Information.  Multiple resources 
are available for further information on human 
(Continued on page 5) 
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Brucellosis. The Control of Communicable Diseases 
Manual, 19th ed. (Heymann, 2008), the 2009 Redbook 
(AAP, 2009), and Principles and Practice of Infectious 
Diseases, 6th ed. (Mandell, 2005), each contain 
informative sections on Brucellosis.  
CDC webpages on Brucellosis are accessible at: http://
www.cdc.gov/ncidod/dbmd/diseaseinfo/
brucellosis_g.htm.   Several issues of the Morbidity and 
Mortality Weekly Report (CDC, 2006, 2009a) have 
addressed Brucellosis, including feral swine transmission 
to processors and laboratory-acquired disease.  
The Compendium of Measures to Prevent Disease 
Associated with Animals in Public Settings, 2009 (CDC, 
2009b), published by the National Association of State 
Public Health Veterinarians, describes the potential 
transfer of Brucellosis and other zoonoses to humans.  
The US Department of Agriculture (USDA) has published 
information for farmers and hunters on Brucella suis in 
feral swine (USDA, 2005).  All of the web-based resources 
listed above are linked from the reference list.  
Reporting.  In South Carolina, Brucellosis is urgently 
reportable; therefore, local health departments should be 
notified of cases within 24 hours of diagnosis. 
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The incidence of brucellosis in the United States has been 
increasing slightly in recent years. Although brucellosis in U.S. 
cattle is in the final stages of eradication, the disease persists in 
feral swine, elk, and bison, increasing the risk of transmission to 
hunters while cleaning and dressing these animals.  Reports of 
human brucellosis cases are more frequent along the southern 
U.S. border, as the disease remains endemic in Mexico. 
Consumption of unpasteurized milk products, including soft 
cheeses from regions where brucellosis is common in cattle, 
sheep, and goats, presents a significant risk.  Outside of the 
United States, brucellosis remains endemic in a number of areas, 
including Mexico and the Mediterranean region, again related to 
consumption of unpasteurized dairy products.  (Edited from CDC, 
2009c, 2007 data). 
Brucellosis. Number of reported [human] cases, — 
United States and U.S. territories, 2007 
Page 6 Fall 2009 Epi Notes 
Influenza-like Illness Surveillance.  The 
Influenza-Like Illness (ILI) network (ILINet) 
monitors the number of patients presenting 
with influenza-like illness.  ILI is defined as: 
fever (>/100 F), cough, and/or a sore throat 
in the absence of other known cause.  
Providers voluntarily submit the number of 
ILIs and total number of patients seen 
weekly via fax or the internet to the CDC.  
Participation is encouraged throughout the 
summer months as well. For the week 
ending September 19, 2009, SC state ILI% 
was 5.67%. SC ILI percentage has been at 
or above the national baseline of 2.4% for 
the past 4 weeks. 
We are currently accepting new ILI 
providers. If you wish to enroll in ILINet, 
contact Chasisity Springs at (803) 898-0870.   
Rapid Antigen Tests.  The total number of positive rapid 
influenza tests are reportable to DHEC within 7 days. Providers 
should submit their weekly reports to the regional health 
department by noon on Monday for the previous week. From 
September 28, 200 to September 26, 2009, there were  39,151 
positive rapid flu tests. During the 2007-2008 season, there 
were 30,235 positive tests from MMWR week 40 (’07) through 
38 (’08).   
Influenza hospitalizations and deaths.  Hospitals are now required to submit the total number of laboratory 
confirmed influenza hospitalizations and deaths (by age group) to DHEC within 7 days.  Reports should be submitted to 
the regional health departments by noon on Monday for the previous week. Laboratory confirmation may include culture, 
RT-PCR, DFA, IFA or rapid test. 
A total of 99 influenza hospitalizations were reported 
by 47 hospitals during the week of September 27—
October 3, 2009. Since September 1, 2009, there 
have been 272 hospitalizations and 9 deaths 
(confirmed associated with H1N1 reported to SC 
DHEC. Death and hospitalization data are updated 
each week at the DHEC Flu Surveillance website: 
http://www.scdhec.gov/health/disease/acute/flu.htm, 
in the weekly FluWatch summary.  
For More Information.  Providers with questions 
regarding either the viral culture network or ILINet 
should contact Chasisity Springs at 
springcb@dhec.sc.gov.  Visit the DHEC flu 
surveillance website at http://www.scdhec.gov/
health/disease/acute/flu.htm. 
(Continued from page 1) 
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Positive rapid test results reported to SC DHEC 
2007-08 vs. 2008-09 
  
9/30/07-
9/27/08 
9/28/08-
9/26/09  
# of positive tests  30,235  39,151 
 Influenza A  11,576  18,294 
 Influenza A/B  16,345  10,062 
 Influenza B  1,812  6,398 
 Unknown  502  204 
Positive confirmatory influenza test results* 
October 4, 2008 – October 3, 2009 
 BOL Other labs 
Number of positive specimens 1106 513 
Pos. specimens by type/subtype     
 Influenza A     
 Influenza A (H1)  144 (13.0%)  1 (0.2%) 
 Influenza A (H3)  46 (4.2%)   
 Influenza A (unsubtyped)  1 (0.1%) 170 (33.1%) 
 Influenza A (novel H1N1)  776 (70.2%) 287 (55.9%) 
 Influenza B  137 (13.5%)  52 (10.1%) 
 Influenza A (H1) and A (H3)  1 (0.1%)   
 Influenza A (H3) and B  1 (0.1%)   
 Unknown    3 (0.6%) 
*Culture and/or RT-PCR 
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Year-to-Date Summary of Reportable Conditions ‡ 
January 1, 2009 to September 15, 2009 
Reportable Condition Confirmed Probable Total 
Animal Bites – PEP recommended 260 * 260 
Arboviral Neuroinvasive Disease (includes West Nile Virus) 0 0 0 
Brucellosis 2 0 2 
Campylobacter enteriditis 182 3 185 
Cryptosporidiosis 43 2 45 
Cyclosporiasis 1 * 1 
Ehrlichiosis 1 2 3 
Enterohemorrhagic E. Coli (includes O157:H7) 0 0 0 
Giardiasis 69 0 69 
Haemophilius influenza 53 0 53 
Hemolytic uremic syndrome 2 0 2 
Hepatitis A, acute 40 * 40 
Hepatitis B, acute 39 2 41 
Hepatitis B, chronic 91 344 435 
Hepatitis C, acute 1 1 2 
Hepatitis C, chronic or past 2,424 30 2,454 
Influenza, positive virus culture isolates (not Novel) 190 * 190 
Influenza, Novel Influenza A Virus Infections (H1N1) 898 4 902 
Legionellosis 7 1 8 
Listeriosis 8 * 8 
Lyme disease 12 8 20 
Malaria 3 * 3 
Measles (rubeola) 0 0 0 
Meningitis, aseptic 65 * 65 
Meningococcal disease 11 1 12 
Mumps 2 0 2 
Pertussis 170 14 184 
Psittacosis 0 1 1 
Rocky Mountain Spotted Fever 3 14 17 
Rubella (includes congenital) 0 0 0 
Salmonellosis 623 8 631 
Shigellosis 91 2 93 
Staphylococcus aureus, vancomycin-resistant (VRSA/VISA) 0 * 0 
Streptococcus group A, invasive disease 61 * 61 
Streptococcus group B, age < 90 days 32 * 32 
Streptococcus pneumoniae, invasive 342 * 342 
Varicella (only outbreak associated or hospitalized cases are reportable) 77 10 87 
Vibrio infections (non-cholera) 11 1 12 
Yersiniosis 8 0 8 
‡   To save space, several conditions with zero reported cases in 2009 were omitted from this list. 
*   Probable cases status is not allowed for this condition.  
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FOR DISEASE REPORTING 
For immediately reportable conditions, call your local county 
health department or, for after hours, call 1-888-847-0902.  
Routine reports may be phoned in to your local health 
department or mailed on a completed DHEC DISEASE 
REPORTING CARD (DHEC 1129.)  Local county health 
department numbers are listed on the Official List of 
Reportable Conditions.   
For a copy of the current Official List of Reportable 
Conditions, call 803-898-0861 or visit www.scdhec.gov/
health/disease.index.htm.  
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